UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION

IN RE: NATIONAL PRESCRIPTION OPIATE LITIGATION

MDL No. 2804

TRANSFER ORDER

Before the Panel:* Plaintiffs in 24 actions move under Panel Rule 7.1 to vacate the orders conditionally transferring their respective actions listed on Schedule A to MDL No. 2804. Various defendants¹ oppose the motions.

After considering the arguments of counsel, we find these actions involve common questions of fact with the actions previously transferred to MDL No. 2804, and that transfer under 28 U.S.C. § 1407 will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. Moreover, transfer is warranted for the reasons set forth in our order directing centralization. In that order, we held that the Northern District of Ohio was an appropriate Section 1407 forum for actions sharing factual questions regarding the allegedly improper marketing and distribution of various prescription opiate medications into states, cities, and towns across the country. *See In re Nat'l Prescription Opiate Litig.*, 290 F. Supp.3d 1375, 1378-79 (J.P.M.L. 2017).

Despite some variances among the actions before us, they share a factual core with the MDL actions: the manufacturer and distributor defendants' alleged knowledge of and conduct regarding the diversion of these prescription opiates, as well as the manufacturers' allegedly improper marketing of the drugs. *See id.* The actions therefore fall within the MDL's ambit.

^{*} Judges Ellen Segal Huvelle and Nathaniel M. Gorton did not participate in the decision of this matter.

Amerisource Drug Corp., Amerisourcebergen Corp. and Amerisourcebergen Drug Corp.; Bellco Drug Corp.; Cardinal Health, Inc., Cardinal Health 110, LLC, Cardinal Health 200, LLC, Cardinal Health 414, LLC; McKesson Corp. (distributor defendants); Allergan PLC, Allergan Finance, LLC; Actavis LLC, Actavis Pharma, Inc.; Barr Laboratories, Inc.; Cephalon, Inc.; Endo Health Solutions Inc., Endo International PLC, Endo Pharmaceuticals, Inc.; Janssen Pharmaceutica, Inc.; Janssen Pharmaceuticals Inc.; Johnson & Johnson; Mallinckrodt plc; Mallinckrodt LLC, Mallinckrodt Brand Pharmaceuticals, Inc.; Ortho-McNeil-Jansenn Pharmaceuticals, Inc.; Par Pharmaceutical, Inc., Par Pharmaceutical Companies, Inc.; Purdue Pharma L.P., Purdue Pharma, Inc., and The Purdue Frederick Company, Inc.; SpecGx LLC; Teva Pharmaceutical Industries Ltd.; Teva Pharmaceuticals USA, Inc., Watson Pharmaceuticals and Watson Laboratories, Inc. (manufacturing defendants); Value Drug Co.

The parties opposing transfer in 24 actions argue principally that federal jurisdiction is lacking over their cases. But opposition to transfer based on a jurisdictional challenge is insufficient to warrant vacating conditional transfer orders covering otherwise factually related cases.² Several parties also argue that including their actions in this large MDL will cause them inconvenience and delay the progress of their actions. Given the undisputed factual overlap with the MDL proceedings, transfer is justified in order to facilitate the efficient conduct of the litigation as a whole. *See In re Watson Fentanyl Patch Prods. Liab. Litig.*, 883 F. Supp. 2d 1350, 1351-52 (J.P.M.L. 2012) ("[W]e look to the overall convenience of the parties and witnesses, not just those of a single plaintiff or defendant in isolation."). Additionally, plaintiff in the District of New Jersey *County of Burlington* action argues that the recent bankruptcy of the Purdue defendants prevents transfer, but we have long rejected that argument. *See In re Ephedra Prods. Liab. Litig.*, 416 F. Supp. 2d 1358, 1359-60 (J.P.M.L. 2006) (transferring actions subject to bankruptcy stay).

IT IS THEREFORE ORDERED that the actions listed on Schedule A are transferred to the Northern District of Ohio and, with the consent of that court, assigned to the Honorable Dan A. Polster for inclusion in the coordinated or consolidated pretrial proceedings.

PANEL ON MULTIDISTRICT LITIGATION

Sarah S. Vance

Chair

Lewis A. Kaplan Catherine D. Perry R. David Proctor Karen K. Caldwell

 $^{^2}$ See, e.g., In re Prudential Ins. Co. of Am. Sales Practices Litig., 170 F. Supp. 2d 1346, 1347-48 (J.P.M.L. 2001).

IN RE: NATIONAL PRESCRIPTION OPIATE LITIGATION

MDL No. 2804

SCHEDULE A

District of Hawaii

COUNTY OF KAUAI v. CVS HEALTH CORPORATION, ET AL., C.A. No. 1:19-00377

Eastern District of Michigan

CHARTER TOWNSHIP OF HARRISON v. THE PAIN CENTER USA, PLLC, ET AL., C.A. No. 2:19–11681

CITY OF STERLING HEIGHTS v. THE PAIN CENTER USA, PLLC, ET AL., C.A. No. 2:19–11685

CITY OF WARREN v. THE PAIN CENTER USA, PLLC, ET AL., C.A. No. 2:19–11687

Eastern District of Missouri

WAMPANOAG TRIBE OF GAY HEAD (AQUINNAH) v. MALLINCKRODT BRAND PHARMACEUTICALS, INC., ET AL., C.A. No. 4:19–01654

ST. FRANCOIS COUNTY v. DANNIE E. WILLIAMS, M.D., ET AL., C.A. No. 4:19–01722

THE CHEROKEE NATION v. MALLINCKRODT PLC, ET AL., C.A. No. 4:19-01911

District of New Jersey

COUNTY OF BURLINGTON v. PURDUE PHARMA L.P., ET AL., C.A. No. 1:19–13684

Eastern District of New York

THE CITY OF AUBURN v. PURDUE PHARMA L.P., ET AL., C.A. No. 2:19-03800

Northern District of New York

THE CITY OF SARATOGA SPRINGS v. PURDUE PHARMA L.P., ET AL., C.A. No. 1:19–00789

THE CITY OF OGDENSBURG v. PURDUE PHARMA L.P., ET AL., C.A. No. 8:19-00782

Western District of New York

THE CITY OF ROCHESTER v. PURDUE PHARMA L.P., ET AL., C.A. No. 6:19-06490

- A2 -

Northern District of Oklahoma

CITY OF JENKS v. PURDUE PHARMA L.P., ET AL., C.A. No. 4:19-00380

Southern District of Texas

ROCKWALL COUNTY, TX v. CVS HEALTH CORPORATION, C.A. No. 4:19–02181 ELLIS COUNTY v. WALGREENS BOOTS ALLIANCE, INC., ET AL., C.A. No. 4:19–02256

COUNTY OF DUVAL v. CVS HEALTH CORPORATION, C.A. No. 4:19-02504

Eastern District of Virginia

- LOUDOUN COUNTY, VIRGINIA v. PURDUE PHARMA, L.P., ET AL., C.A. No. 1:19–00778
- CITY OF PORTSMOUTH v. MCKESSON CORPORATION, ET AL., C.A. No. 2:19–00331
- CITY OF FREDERICKSBURG, VIRGINIA v. PURDUE PHARMA, L.P., ET AL., C.A. No. 3:19–00457
- PRINCE GEORGE COUNTY, VIRGINIA v. PURDUE PHARMA, L.P., ET AL., C.A. No. 3:19-00458
- GREENSVILLE COUNTY, VIRGINIA v. PURDUE PHARMA, L.P., ET AL., C.A. No. 3:19–00459
- CITY OF EMPORIA, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 3:19-00513

Western District of Virginia

CULPEPER COUNTY, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 3:19-00037

CHARLOTTE COUNTY, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 4:19–00029